Please login to the form below

Not currently logged in
Email:
Password:

JPA adds to Washington team

Jeff Goldfarb to join PR agency as VP
JPA Jeff Goldfarb

JPA Health Communications has expanded its Washingtom team with the appointment of Jeff Goldfarb as VP.

Goldfarb has two decades' experience in marketing, branding and communications, said JPA, with significant experience in the healthcare industry. He joins from Matthews Media Group (MMG).

As VP and senior strategist at MMG, Goldfarb developed communications plans and ran patient recruitment initiatives of clinical trials. He also managed public health communications programmes for the Food and Drug Administration and National Cancer Institute.

Before joining MMG, Goldfarb worked on marketing programmes for products such as Claritin and Glucophage. He previously worked for the agency Trahan, Burden, Charles where he managed marketing objectives for the likes of Blue Cross Blue Shield of Maryland and the Baltimore Ravens.

In his new role Goldfarb will 'lead several client projects, participate in new business efforts and support staff development', JPA told PMLiVE. He will support pharmaceutical clients and non-profit organisations, and will start out with a team of four.

“We are thrilled to welcome Jeff to the agency,” said Carrie Jones, principal and managing director of JPA. “His extensive communications experience in the healthcare industry will help us deliver the high-quality results our clients expect.”

30th January 2014

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics